AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6490470 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm drinks
Number of subjects: 29
Study 6490470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool drinks
Number of subjects: 29
Study 6490470 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm iodine-treated water
Number of subjects: 29
Study 28661984 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 28661984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28661984 — intervention group
Group type: EXPERIMENTAL
Intervention: Burned children
Number of subjects: 20
Study 28661984 — intervention group
Group type: COMPARATOR
Intervention: Nonburned children
Number of subjects: 20
Study 28054924 — intervention group
Group type: EXPERIMENTAL
Intervention: Braden Scale assessment by nurses and research staff
Number of subjects: 64
Study 28054924 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative survey of nurses' perspectives
Number of subjects: 64
Study 24738161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam (PIV)
Number of subjects: 1143
Study 24738161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1143
Study 22410469 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position for 6 min before assuming wedged supine position (group L)
Number of subjects: 86
Study 22410469 — intervention group
Group type: COMPARATOR
Intervention: Wedge supine position immediately after spinal injection (group S)
Number of subjects: 86
Study 20488453 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective head cooling
Number of subjects: 194
Study 20488453 — intervention group
Group type: COMPARATOR
Intervention: Control (rectal temperature maintained at 36.0 to 37.5 degrees C)
Number of subjects: 194
Study 20488453 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 194
Study 18367694 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-based training
Number of subjects: 18
Study 18367694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence-based training
Number of subjects: 18
Study 18367694 — intervention group
Group type: COMPARATOR
Intervention: Phoneme-based training
Number of subjects: 18
Study 16315159 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 93
Study 16315159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 12432412 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS Program (family involvement, optimistic attitude, coping effectiveness, uncertainty reduction, and symptom management) delivered in three home visits and two follow-up phone calls over a five-month period.
Number of subjects: 0
Study 10487480 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous LDL
Number of subjects: 49
Study 10487480 — intervention group
Group type: COMPARATOR
Intervention: Homologous LDL
Number of subjects: 49
Study 10487480 — intervention group
Group type: EXPERIMENTAL
Intervention: XbaI -/- genotype
Number of subjects: 49
Study 10487480 — intervention group
Group type: EXPERIMENTAL
Intervention: EcoRI +/+ genotype
Number of subjects: 49
Study 10487480 — intervention group
Group type: EXPERIMENTAL
Intervention: apo E 4 genotype
Number of subjects: 49
Study 10487480 — intervention group
Group type: EXPERIMENTAL
Intervention: apo B polymorphisms
Number of subjects: 49
Study 8594280 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture Training Support (PTS)
Number of subjects: 45
Study 8594280 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional thoracolumbar support
Number of subjects: 45
Study 8594280 — intervention group
Group type: COMPARATOR
Intervention: Postural exercise only (Control)
Number of subjects: 45
Study 1673123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lorazepam 2 mg
Number of subjects: 0
Study 1673123 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol 5 mg
Number of subjects: 0
Study 6754416 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (200 micrograms and 400 micrograms per day)
Number of subjects: 36
Study 6754416 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (long-term use for more than two years)
Number of subjects: 36
Study 31141514 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing at health centers
Number of subjects: 0
Study 31141514 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing at referral hospitals
Number of subjects: 0
Study 31141514 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line ART
Number of subjects: 0
Study 31141514 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line ART
Number of subjects: 0
Study 31141514 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care at referral and provincial hospitals
Number of subjects: 0
Study 28937065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 40
Study 28937065 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (i.v. CyP)
Number of subjects: 40
Study 25346067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 20
Study 25346067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24621999 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice a day
Number of subjects: 20
Study 24621999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21355150 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-catgut-embedding therapy combined with conventional western medication
Number of subjects: 60
Study 21355150 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medication
Number of subjects: 60
Study 19819660 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation skills training (CST) program
Number of subjects: 375
Study 19819660 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 375
Study 16879517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg x kg(‐1) iv
Number of subjects: 42
Study 16879517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12762871 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic electrical capsular stimulation (stimulation-on condition)
Number of subjects: 6
Study 12762871 — intervention group
Group type: COMPARATOR
Intervention: Postoperative stimulator-off condition
Number of subjects: 6
Study 12762871 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic electrical capsular stimulation
Number of subjects: 6
Study 12762871 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PET scans vs. 3 months of stimulation
Number of subjects: 6
Study 11404138 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (SKT without opening pleurae)
Number of subjects: 299
Study 11404138 — intervention group
Group type: COMPARATOR
Intervention: Group II (pedunculated technique with open pleurae)
Number of subjects: 299
Study 11404138 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (SKT with incidentally opened pleurae)
Number of subjects: 299
Study 11404138 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 299
Study 11404138 — intervention group
Group type: COMPARATOR
Intervention: Group II
Number of subjects: 299
Study 11404138 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III
Number of subjects: 299
Study 9236572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% tropicamide
Number of subjects: 101
Study 9236572 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 101
Study 7658972 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) administered at 25 U/kg/dose, i.v. route, three times weekly, adjusted according to hematimetric response.
Number of subjects: 18
Study 7658972 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) treatment.
Number of subjects: 18
Study 3300135 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel, 0.5 mg (2.5 ml)
Number of subjects: 416
Study 3300135 — intervention group
Group type: COMPARATOR
Intervention: Non-gel control
Number of subjects: 416
Study 31045610 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention applied during hemodialysis, with 12 applications over 1 month.
Number of subjects: 186
Study 31045610 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group) during hemodialysis.
Number of subjects: 186
Study 28111095 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention focused on training teachers, providing opportunities for physical activity in the school environment, and health education over four months.
Number of subjects: 1085
Study 28111095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 1085
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase ≤143 U/l
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-specific alkaline phosphatase (BSAP) <146 U/l
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected urinary N-telopeptide (uNTx) ≤50 nmol/mmol
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild or no pain (BPI-SF score ≤4)
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: No previous skeletal-related event (SRE)
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time from initial diagnosis to first bone metastasis
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time from first bone metastasis to randomization
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) level <10 ng/ml
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin >128g/l
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of visceral metastases
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastern Cooperative Oncology Group (ECOG) score ≤1
Number of subjects: 1901
Study 25449207 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1901
Study 22759078 — intervention group
Group type: EXPERIMENTAL
Intervention: OZ439 (50-1200 mg as capsule; 400-1600 mg as oral dispersion)
Number of subjects: 0
Study 22759078 — intervention group
Group type: EXPERIMENTAL
Intervention: OZ439 (200-800 mg/day for 3 days as oral dispersion)
Number of subjects: 0
Study 22759078 — intervention group
Group type: EXPERIMENTAL
Intervention: OZ439
Number of subjects: 0
Study 21724705 — intervention group
Group type: EXPERIMENTAL
Intervention: CH-1504 (0.25 mg, 0.5 mg, or 1.0 mg once-daily oral doses)
Number of subjects: 201
Study 21724705 — intervention group
Group type: COMPARATOR
Intervention: MTX (titrated to 20.0 mg once-weekly oral doses)
Number of subjects: 201
Study 21724705 — intervention group
Group type: EXPERIMENTAL
Intervention: CH-1504
Number of subjects: 201
Study 21724705 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 201
Study 18095967 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg.kg(‐1)
Number of subjects: 84
Study 18095967 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 84
Study 16522392 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g calcium/d)
Number of subjects: 8325
Study 16522392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8325
Study 12673721 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-cm margin
Number of subjects: 326
Study 12673721 — intervention group
Group type: COMPARATOR
Intervention: 5-cm margin
Number of subjects: 326
Study 12673721 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (adjuvant treatment)
Number of subjects: 326
Study 12673721 — intervention group
Group type: COMPARATOR
Intervention: Observation (control for Isoprinosine)
Number of subjects: 326
Study 10903017 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (15 mg/min) added to cold blood cardioplegia
Number of subjects: 40
Study 10903017 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 40
Study 9021698 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) after high dose therapy
Number of subjects: 44
Study 8256950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free formula
Number of subjects: 60
Study 8256950 — intervention group
Group type: COMPARATOR
Intervention: Lactose containing formula
Number of subjects: 60
Study 3899398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef (750 mg mefloquine, 1500 mg sulfadoxine, 75 mg pyrimethamine)
Number of subjects: 20
Study 3899398 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (Fansidar)
Number of subjects: 20
Study 30947642 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 119
Study 30947642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 28985286 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational-support strategies (e.g. manager support, emails) with activity tracker
Number of subjects: 153
Study 28985286 — intervention group
Group type: COMPARATOR
Intervention: Organizational-support strategies (e.g. manager support, emails) without activity tracker
Number of subjects: 153
Study 28985286 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational-support strategies (with or without activity tracker)
Number of subjects: 153
Study 25891131 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-RPDs
Number of subjects: 54
Study 25891131 — intervention group
Group type: COMPARATOR
Intervention: C-RPDs
Number of subjects: 54
Study 24315492 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection + thumb spica cast (CSI + TSC)
Number of subjects: 67
Study 24315492 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI)
Number of subjects: 67
Study 22673486 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) 200 units (Dysport)
Number of subjects: 40
Study 20479569 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy for 6 months
Number of subjects: 6
Study 20479569 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of growth hormone therapy for 12 months
Number of subjects: 6
Study 18362722 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax expander
Number of subjects: 40
Study 18362722 — intervention group
Group type: EXPERIMENTAL
Intervention: Haas expander
Number of subjects: 40
Study 15994622 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (25-mug daily dose of ethinyl estradiol)
Number of subjects: 201
Study 15994622 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive vaginal ring (15-mug daily dose of ethinyl estradiol)
Number of subjects: 201
Study 15994622 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive vaginal ring
Number of subjects: 201
Study 15994622 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive
Number of subjects: 201
Study 15994622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 201
Study 12622108 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (group B) using propofol and remifentanil infusions
Number of subjects: 100
Study 12622108 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia (group A) using fentanyl, propofol and isoflurane
Number of subjects: 100
Study 12622108 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (group B)
Number of subjects: 100
Study 10589958 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy findings with evidence of fibrosis, tubular atrophy, or CD3gamma transcription
Number of subjects: 40
Study 10589958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine transcripts and histological evidence of injury
Number of subjects: 40
Study 10589958 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of lymphocytic infiltrate
Number of subjects: 40
Study 10589958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrigraft CD3y transcription
Number of subjects: 40
Study 10589958 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 and IL-8 transcripts
Number of subjects: 40
Study 8735328 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational audiotapes
Number of subjects: 75
Study 8735328 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study 8102305 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SASP)
Number of subjects: 89
Study 8102305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 8102305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 2423788 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 25 mg three times daily
Number of subjects: 15
Study 2423788 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 0.2 mg/kg i.v.
Number of subjects: 15
Study 30546229 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental A group (conventional, noninvasive treatment with raj‐yoga meditation therapy and pranayama)
Number of subjects: 30
Study 30546229 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional, noninvasive treatment)
Number of subjects: 30
Study 30546229 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental B group (Raj‐yoga meditation therapy and pranayama only)
Number of subjects: 30
Study 27776506 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component workplace health promotion (WHP) intervention including intelligent physical exercise training (IPET), dietary advice and weight loss (DAW), and cognitive behavioural training (CBT)
Number of subjects: 0
Study 27776506 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component workplace health promotion (WHP) intervention
Number of subjects: 0
Study 25359348 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once daily
Number of subjects: 581
Study 25359348 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 581
Study 22407003 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30
Study 22407003 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate 0.1% ointment
Number of subjects: 30
Study 22046746 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronectomy
Number of subjects: 0
Study 22046746 — intervention group
Group type: COMPARATOR
Intervention: Total removal of wisdom teeth
Number of subjects: 0
Study 18268285 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg
Number of subjects: 90
Study 18268285 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 12 mg
Number of subjects: 90
Study 18268285 — intervention group
Group type: EXPERIMENTAL
Intervention: filgrastim 5 mug/kg/day
Number of subjects: 90
Study 16502351 — intervention group
Group type: EXPERIMENTAL
Intervention: Prinomastat
Number of subjects: 15
Study 16502351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12391130 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum strength (MS) resistance exercise protocol: 4 sets x 5 reps at 88% of 1 RM with 3 min rest
Number of subjects: 10
Study 12391130 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular hypertrophy (MH) resistance exercise protocol: 4 sets x 10 reps at 75% of 1 RM with 2 min rest
Number of subjects: 10
Study 12391130 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength endurance (SE) resistance exercise protocol: 4 sets x 15 reps at 60% of 1 RM with 1 min rest
Number of subjects: 10
Study 12391130 — intervention group
Group type: COMPARATOR
Intervention: Control (C) session
Number of subjects: 10
Study 10440212 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon-alpha regimen 1 (780 million units over 6 months)
Number of subjects: 44
Study 10440212 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon-alpha regimen 2 (840 million units over 6 months)
Number of subjects: 44
Study 7927247 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor therapy
Number of subjects: 9
Study 2595643 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 25 mg
Number of subjects: 12
Study 2595643 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 50 mg
Number of subjects: 12
Study 2595643 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 75 mg
Number of subjects: 12
Study 2595643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1103916 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of diazepam 10 mg
Number of subjects: 8
Study 1103916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration into the deltoid muscle of diazepam 10 mg
Number of subjects: 8
Study 1103916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration into the vastus lateralis muscle of diazepam 10 mg
Number of subjects: 8
Study 31577085 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g intravenous vitamin C
Number of subjects: 101
Study 31577085 — intervention group
Group type: COMPARATOR
Intervention: 100 mg aceclofenac
Number of subjects: 101
Study 28485987 — intervention group
Group type: EXPERIMENTAL
Intervention: Gate questions
Number of subjects: 1048
Study 28485987 — intervention group
Group type: COMPARATOR
Intervention: No gate questions
Number of subjects: 1048
Study 25948717 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LVT)
Number of subjects: 121
Study 25948717 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 121
Study 23332020 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention targeting reducing smoking initiation
Number of subjects: 36
Study 23332020 — intervention group
Group type: COMPARATOR
Intervention: Increasing homework (control group)
Number of subjects: 36
Study 21575187 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS treatment for TB patients
Number of subjects: 6450